Century Therapeutics, Inc. (IPSC): Price and Financial Metrics
IPSC Price/Volume Stats
| Current price | $1.10 | 52-week high | $5.51 |
| Prev. close | $1.05 | 52-week low | $0.98 |
| Day low | $1.05 | Volume | 1,021,500 |
| Day high | $1.12 | Avg. volume | 318,089 |
| 50-day MA | $1.38 | Dividend yield | N/A |
| 200-day MA | $2.38 | Market Cap | 93.53M |
IPSC Stock Price Chart Interactive Chart >
Century Therapeutics, Inc. (IPSC) Company Bio
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
IPSC Price Returns
| 1-mo | -11.29% |
| 3-mo | -35.29% |
| 6-mo | -58.96% |
| 1-year | -54.55% |
| 3-year | -93.62% |
| 5-year | N/A |
| YTD | -66.87% |
| 2023 | -35.28% |
| 2022 | -67.65% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...